Outcomes of patients with relapsed/refractory double-expressor B-cell lymphoma treated with ibrutinib monotherapy

The B-cell receptor signaling pathway is active in diffuse large B-cell lymphomas, with increased expression of MYC and BCL2 protein. The overall response rate was 60% for relapsed/refractory non–germinal center double-expressor lymphoma patients treated with ibrutinib.

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Blood Adv
Egile Nagusiak: Landsburg, Daniel J., Hughes, Mitchell E., Koike, Alexa, Bond, David, Maddocks, Kami J., Guo, Ling, Winter, Allison M., Hill, Brian T., Ondrejka, Sarah L., Hsi, Eric D., Nasta, Sunita D., Svoboda, Jakub, Schuster, Stephen J., Bogusz, Agata M.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2019
Gaiak:
Stimulus Report
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC6341198/
https://ncbi.nlm.nih.gov/pubmed/30651281
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2018026401
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak